The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Use of ibuprofen and risk of Parkinson disease
Open accessAbstract
BACKGROUND: Neuroinflammation may contribute to the pathogenesis of Parkinson disease (PD). Use of nonsteroidal anti-inflammatory drugs (NSAID) in general, and possibly ibuprofen in particular, has been shown to be related to lower PD risk in previous epidemiologic studies. METHODS: We prospectively examined whether use of ibuprofen or other NSAIDs is associated with lower PD risk among 136,197 participants in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) free of PD at baseline (1998 for NHS and 2000 for HPFS). NSAIDs use was assessed via questionnaire. Results were combined in a meta-analysis with those of published prospective investigations. RESULTS: We identified 291 incident PD cases during 6 years of follow-up. Users of ibuprofen had a significantly lower PD risk than nonusers (relative risk [RR], adjusted for age, smoking, caffeine, and other covariates = 0.62; 95% confidence interval [CI] 0.42-0.93; p = 0.02). There was a dose-response relationship between tablets of ibuprofen taken per week and PD risk (p trend = 0.01). In contrast, PD risk was not significantly related to use of aspirin (RR = 0.99; 95% CI 0.78-1.26), other NSAIDs (RR = 1.26; 95% CI 0.86-1.84), or acetaminophen (RR = 0.86; 95% CI 0.62-1.18). Similar results were obtained in the meta-analyses: the pooled RR was 0.73 (95% CI 0.63-0.85; p < 0.0001) for ibuprofen use, whereas use of other types of analgesics was not associated with lower PD risk. CONCLUSIONS: The association between use of ibuprofen and lower PD risks, not shared by other NSAIDs or acetaminophen, suggests ibuprofen should be further investigated as a potential neuroprotective agent against PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Feskanich, D., Rimm, E. B., Giovannucci, E. L., Colditz, G. A., Stampfer, M. J., Litin, L. B., & Willett, W. C. (1993) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(93)91754-e · Cited by 1,070
SALVINI, S., HUNTER, D. J., SAMPSON, L., STAMPFER, M. J., COLDITZ, G. A., ROSNER, B., & WILLETT, W. C. (1989) · International Journal of Epidemiology · doi:10.1093/ije/18.4.858 · Cited by 1,038
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677
Self-citationNonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Self-citationMeta-analysis of Epidemiologic Dose-Response Data
Berlin, J. A., Longnecker, M. P., & Greenland, S. (1993) · Epidemiology · doi:10.1097/00001648-199305000-00005 · Cited by 571
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472
Self-citationPlasma Urate and Risk of Parkinson's Disease
Weisskopf, M., O'Reilly, E., Chen, H., Schwarzschild, M., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 390
Self-citationAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysis
Gagne, J. J., & Power, M. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5a4a3 · Cited by 322
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Dopamine‐related personality traits in Parkinson's disease
Menza, M. A., Golbe, L. I., Cody, R. A., & Forman, N. E. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.505 · Cited by 247
Non-steroidal anti-inflammatory drugs in Parkinson's disease
Esposito, E., Di Matteo, V., Benigno, A., Pierucci, M., Crescimanno, G., & Di Giovanni, G. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.008 · Cited by 234
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2007) · Neurology · doi:10.1212/01.wnl.0000279519.99344.ad · Cited by 213
Paulose‐Ram, R., Hirsch, R., Dillon, C., Losonczy, K., Cooper, M., & Ostchega, Y. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.755 · Cited by 198
Lifetime Nonnarcotic Analgesic Use and Decline in Renal Function in Women
Curhan, G. C., Knight, E. L., Rosner, B., Hankinson, S. E., & Stampfer, M. J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1519 · Cited by 166
Gout and risk of Parkinson disease: A prospective study
Alonso, A., Rodríguez, L. A. G., Logroscino, G., & Hernán, M. A. (2007) · Neurology · doi:10.1212/01.wnl.0000279518.10072.df · Cited by 166
Samii, A., Etminan, M., Wiens, M. O., & Jafari, S. (2009) · Drugs & Aging · doi:10.2165/11316780-000000000-00000 · Cited by 161
PPAR: a therapeutic target in Parkinson’s disease
Chaturvedi, R. K., & Beal, M. F. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05388.x · Cited by 159
Diet, Urate, and Parkinson's Disease Risk in Men
Gao, X., Chen, H., Choi, H. K., Curhan, G. C., Schwarzschild, M. A., & Ascherio, A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm385 · Cited by 151
Self-citationNonnarcotic Analgesic Use and the Risk of Hypertension in US Women
Dedier, J., Stampfer, M. J., Hankinson, S. E., Willett, W. C., Speizer, F. E., & Curhan, G. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000035856.77718.da · Cited by 145
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk
Powers, K. M., Kay, D. M., Factor, S. A., Zabetian, C. P., Higgins, D. S., Samii, A., Nutt, J. G., Griffith, A., Leis, B. C., Roberts, J. W., et al. (2007) · Movement Disorders · doi:10.1002/mds.21782 · Cited by 144
Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Jr., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Movement Disorders · doi:10.1002/mds.20856 · Cited by 141
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
Hernán, M. Á., Logroscino, G., & Rodríguez, L. A. G. (2006) · Neurology · doi:10.1212/01.wnl.0000204446.82823.28 · Cited by 139
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
Casper, D., Yaparpalvi, U., Rempel, N., & Werner, P. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01294-5 · Cited by 138
Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study
Bower, J. H., Maraganore, D. M., Peterson, B. J., Ahlskog, J. E., & Rocca, W. A. (2006) · Neurology · doi:10.1212/01.wnl.0000227906.99570.cc · Cited by 123
Genetic determinants of hair color and parkinson's disease risk
Gao, X., Simon, K. C., Han, J., Schwarzschild, M. A., & Ascherio, A. (2009) · Annals of Neurology · doi:10.1002/ana.21535 · Cited by 116
Self-citationSmoking, Caffeine, and Nonsteroidal Anti-inflammatory Drugs in Families With Parkinson Disease
Hancock, D. B., Martin, E. R., Stajich, J. M., Jewett, R. M., Stacy, M. A., Scott, B. L., Vance, J. M., & Scott, W. K. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.576 · Cited by 109
Milatović, D., Zaja‐Milatovic, S., Montine, K. S., Horner, P. J., & Montine, T. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02120.x · Cited by 101
Prospective Study of Aspirin Use and Risk of Stroke in Women
Iso, H., Hennekens, C. H., Stampfer, M. J., Rexrode, K. M., Colditz, G. A., Speizer, F. E., Willett, W. C., & Manson, J. E. (1999) · Stroke · doi:10.1161/01.str.30.9.1764 · Cited by 95
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Bornebroek, M., de Lau, L. M. L., Haag, M. D. M., Koudstaal, P. J., Hofman, A., Stricker, B. H. C., & Breteler, M. M. B. (2007) · Neuroepidemiology · doi:10.1159/000108110 · Cited by 85
Etminan, M., Carleton, B., & Samii, A. (2008) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2007.02.095 · Cited by 64
Inflammation in Parkinson's disease: an update.
Smith, P. F. (2008) · PubMed · Cited by 48
Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Asanuma, M., & Miyazaki, I. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480153 · Cited by 48
How do patients with parkinsonism present? A clinicopathological study
Williams, D. R., & Lees, A. J. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01635.x · Cited by 44
Common anti-inflammatory drugs are potentially therapeutic for Parkinson’s disease?
Asanuma, M., & Miyazaki, I. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.006 · Cited by 31
Tsuji, T., Asanuma, M., Miyazaki, I., Miyoshi, K., & Ogawa, N. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9863-x · Cited by 27
NSAID Use and the Risk of Parkinsons Disease
Etminan, M., & Suissa, S. (2006) · Current Drug Safety · doi:10.2174/157488606777934404 · Cited by 27
Ibuprofen and the mouse model of Parkinson's disease
Kurkowska‐Jastrzębska, I., Członkowski, A., & Członkowska, A. (2006) · Annals of Neurology · doi:10.1002/ana.20860 · Cited by 13
Migraine with aura. A risk factor for unprovoked seizures in children?
Wöber, C., & Wöber‐Bingöl, Ç. (2006) · Annals of Neurology · doi:10.1002/ana.20842 · Cited by 10
Cited by
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,825
Self-citationRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
The epidemiology of Parkinson's disease
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., & Tanner, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01419-8 · Cited by 967
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Metadata
- Authors
- Gao, X., Chen, H., Schwarzschild, M. A., & Ascherio, A.
- Venue
- Neurology
- Published
- 2011-03-08
- Volume
- 76
- Issue
- 10
- Pages
- 863-869
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2037752501
- Cited by
- 321
- References
- 40
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.